

RESEARCH MONOGRAPH . COMPOUND PROFILE

ITPP

A first-in-class inositol pyrophosphate designed to cross the erythrocyte membrane, reduce hemoglobin oxygen affinity via right-shift of the oxyhemoglobin dissociation curve, and enhance regulated oxygen delivery to hypoxic tissues, with preclinical and early clinical investigation across oncology, cardiovascular, and metabolic indications.

DOCUMENT	KDC-MN-1531
ISSUED	2026-05-15
REVISION	1.0
AUTHOR	Kodiac biolabs Research
COMPOUND CLASS	Synthetic membrane-permeant allosteric effector of hemoglobin (inositol pyrophosphate class)

ABSTRACT

Myo-inositol trispyrophosphate (ITPP) is a synthetic pyrophosphate derivative of phytic acid that functions as a membrane-permeant allosteric effector of hemoglobin, reducing the affinity of hemoglobin for oxygen and shifting the oxyhemoglobin dissociation curve to the right, thereby enhancing the release of molecular oxygen from erythrocytes into tissues under conditions of low partial pressure of oxygen. The compound was conceived in the laboratory of Jean-Marie Lehn (Nobel Laureate in Chemistry, 1987) and Claude Nicolau in the early 2000s as a rationally designed analog of the endogenous erythrocyte effector 2,3-diphosphoglycerate (2,3-DPG), engineered to bear three cyclic pyrophosphate rings on the myo-inositol scaffold that confer net negative charge sufficient to bind the positively charged central cavity of deoxyhemoglobin while maintaining membrane permeability across the erythrocyte plasma membrane via the band 3 anion transport complex. Unlike 2,3-DPG and the structurally related phytic acid (inositol hexakisphosphate), which cannot traverse the red blood cell membrane, ITPP enters the erythrocyte intact and engages the allosteric T-state binding site of hemoglobin in situ, producing a dose-dependent rightward shift of the P50 (the partial pressure of oxygen at which hemoglobin is 50 percent saturated) without altering cooperativity or total oxygen-carrying capacity.

The preclinical pharmacology of ITPP spans three principal therapeutic domains. In oncology, ITPP-mediated tumor reoxygenation produces downregulation of hypoxia-inducible factor 1-alpha (HIF-1alpha) and vascular endothelial growth factor

(VEGF), normalization of tumor vasculature through activation of the endothelial PTEN/AKT signaling axis, and potentiation of subsequent chemotherapy and radiation therapy in rodent models of pancreatic, hepatocellular, colorectal, melanoma, glioblastoma, and rhabdomyosarcoma tumors. In cardiovascular medicine, ITPP treatment in rodent models of myocardial infarction and monocrotaline-induced pulmonary hypertension has produced improved myocardial oxygenation, attenuation of adverse left and right ventricular remodeling, reduction of pulmonary hypertension-related mortality, and dose-dependent increases in maximal exercise capacity of up to 57 percent in normal mice and 63 percent in transgenic mice with severe heart failure. In metabolism, ITPP has demonstrated reduction of adipose tissue accumulation in high-fat-diet rodent models through reversal of adipose tissue hypoxia.

The compound entered clinical development under the designation OXY111A through Normoxys, Inc. A Phase Ib dose-escalation study (NCT02528526) conducted at University Hospital Zurich enrolled 28 patients with advanced hepatopancreatobiliary malignancies and colorectal cancer liver metastases across eight dose levels (1,866 to 14,500 mg/m² per dose), administered as nine 8-hour intravenous infusions over three weeks. The maximum tolerated dose was established at 12,390 mg/m². The compound was well tolerated, with the principal treatment-related adverse event being asymptomatic hypercalcemia attributable to calcium chloride in the formulation rather than to the compound itself. Pharmacokinetic analysis demonstrated dose-proportional exposure with a terminal half-life of 1.3 to 3.3 hours, no systemic accumulation, and plasma clearance of 3.1 to 4.8 L/h. Morphological disease stabilization was observed in 52 percent of patients under ITPP monotherapy, and subsequent

chemotherapy produced stable disease in 60 percent and partial response in 10 percent. Decreases in circulating angiogenic markers (VEGFA, angiopoietin-1, angiopoietin-2, EGF, PECAM1) were observed in a majority of patients and correlated with improved survival following chemotherapy. ITPP is prohibited in competitive sport by the World Anti-Doping Agency as a substance with potential to enhance oxygen transfer, and analytical methods for its detection in human urine and equine plasma have been developed for anti-doping enforcement.

1. Compound Identification

1.1 Names, synonyms, and registry identifiers

Preferred name: Myo-inositol trispyrophosphate (ITPP).

Development code: OXY111A (Normoxys, Inc.). The development code is the identifier used in the Phase Ib clinical trial program and in regulatory filings.

Systematic name (IUPAC): Myo-inositol, cyclic 1,2:3,4:5,6-tris(P,P'-dihydrogen diphosphate). The compound is formally a tris-cyclic pyrophosphate ester of the six hydroxyl groups of myo-inositol, with three seven-membered cyclic pyrophosphate rings bridging positions 1,2; 3,4; and 5,6 of the inositol ring.

Chemical Abstracts Service registry numbers: 623552-11-4 (free acid form); 23103-35-7 (hexasodium salt); 802590-64-3 (alternative registry); 851086-77-6 (hexatriethylamine salt). The hexasodium salt is the most commonly supplied research-grade preparation and the form used in the clinical formulation OXY111A.

Other designations: Inositol tripyrophosphate; ITPP hexasodium; myo-inositol tris(pyrophosphate).

1.2 Structural class and chemistry

ITPP is an inositol pyrophosphate, a synthetic member of the broader class of inositol polyphosphates that includes the endogenous signaling molecules inositol 1,4,5-trisphosphate (IP3), inositol hexakisphosphate (phytic acid, IP6), and the diphosphoinositol polyphosphates (PP-InsP5, also known as IP7) [1]. The compound is distinguished from naturally occurring inositol phosphates by the presence of three cyclic pyrophosphate linkages rather than simple phosphomonoester groups.

Molecular formula: C₆H₁₂O₂₁P₆ (free acid form).

Molecular weight: 605.98 g/mol (free acid); the hexasodium salt molecular weight is approximately 737.85 g/mol.

Physical properties: White to off-white hygroscopic powder. Freely soluble in water as the hexasodium salt. The free acid form is also water-soluble under neutral to alkaline conditions. The compound is not soluble in most organic solvents. Storage at 2 to 8 degrees Celsius under desiccation is recommended; the compound is stable in the solid state for at least 24 months under these conditions.

Structural rationale: The three cyclic pyrophosphate rings generate six negative charges at physiological pH, enabling electrostatic interaction with the positively charged residues lining the central cavity of the deoxyhemoglobin tetramer (the same binding site occupied by 2,3-DPG). The cyclic pyrophosphate configuration, rather than the open-chain phosphomonoester configuration of IP6 (phytic acid), confers the critical property of membrane permeability across the erythrocyte plasma membrane via the band 3 anion exchange complex (SLC4A1, also known as AE1), the most abundant integral membrane protein of the human erythrocyte [2, 3].

1.3 Synthesis

The synthesis of ITPP was first reported by Nicolau, Lehn, and colleagues and proceeds from myo-inositol as the starting material [2, 3]. The key transformation is the selective cyclic pyrophosphorylation of the three pairs of vicinal hydroxyl groups (1,2; 3,4; 5,6) on the inositol ring. Published approaches employ phosphoramidite chemistry or phosphoryl chloride-based reagents to install the pyrophosphate bridges, followed by oxidation and deprotection to yield the fully unmasked tris-cyclic pyrophosphate. The hexasodium salt is prepared by titration with sodium hydroxide or by ion exchange chromatography. Purification is achieved by ion exchange chromatography, size exclusion chromatography, or preparative high-performance liquid chromatography. The compound is characterized by phosphorus-31 nuclear magnetic resonance spectroscopy, mass spectrometry (electrospray ionization, negative mode), and elemental analysis. Industrial-scale synthesis for the clinical OXY111A formulation has been performed under Good Manufacturing Practice conditions. Overall synthetic yields are moderate; the principal challenge is selectivity of the cyclic pyrophosphorylation across the three vicinal diol pairs without formation of open-chain polyphosphate byproducts.

2. Abstract

Myo-inositol trispyrophosphate (ITPP) is a rationally designed, first-in-class synthetic allosteric effector of hemoglobin that enhances the release of oxygen from erythrocytes to hypoxic tissues by shifting the oxyhemoglobin dissociation curve to the right [2, 3]. The compound was developed in the laboratories of Jean-Marie Lehn and Claude Nicolau as a membrane-permeant analog of 2,3-diphosphoglycerate (2,3-DPG), the endogenous erythrocyte metabolite that modulates hemoglobin oxygen affinity. Unlike 2,3-DPG and the structurally related inositol hexakisphosphate (phytic acid, IP6), which are unable to cross the erythrocyte membrane, ITPP enters the red blood cell via the band 3 anion transport complex and binds the central cavity of deoxyhemoglobin, stabilizing the low-affinity T-state conformation and increasing the P50 in a dose-dependent manner without altering cooperativity or total oxygen-carrying capacity [2].

The principal therapeutic hypothesis is that pharmacological enhancement of oxygen unloading from hemoglobin can reverse tissue hypoxia in pathological states where oxygen delivery is compromised, including solid tumor hypoxia, ischemic cardiovascular disease, pulmonary hypertension, and adipose tissue hypoxia in obesity. In oncology, this hypothesis has been validated in preclinical models across at least seven tumor types, where ITPP-mediated reoxygenation produced suppression of HIF-1 α signaling, downregulation of VEGF, normalization of tumor vasculature, and potentiation of both chemotherapy and radiation therapy [4, 5, 6, 7, 8]. In cardiovascular models, ITPP produced dose-dependent increases in exercise capacity in mice with severe heart failure and attenuated right ventricular failure in monocrotaline-induced pulmonary hypertension [9, 10, 11].

The compound entered clinical development as OXY111A. A Phase Ib dose-escalation study in 28 patients with advanced hepatopancreatobiliary malignancies established the maximum tolerated dose at 12,390 mg/m², demonstrated favorable tolerability with asymptomatic hypercalcemia as the principal treatment-emergent toxicity, and showed morphological disease stabilization in 52 percent of patients under monotherapy with reductions in circulating angiogenic markers correlating with improved survival following subsequent chemotherapy [12, 13]. ITPP is classified as a prohibited substance by the World Anti-Doping Agency (WADA) under the

category of substances with potential to enhance oxygen transfer, and detection methods for human and equine anti-doping enforcement have been developed [14, 15, 16].

3. Discovery and Development History

3.1 Origin and rationale

The concept underlying ITPP emerged from the intersection of supramolecular chemistry and hemoglobin physiology. Jean-Marie Lehn, who received the Nobel Prize in Chemistry in 1987 for his foundational work in supramolecular chemistry and host-guest recognition, collaborated with Claude Nicolau (a biophysicist and lipid membrane specialist) to design a synthetic molecule capable of mimicking the allosteric function of 2,3-DPG while possessing the critical property of membrane permeability that 2,3-DPG lacks [2, 3]. The design constraints were (a) sufficient negative charge density to engage the positively charged central cavity of deoxyhemoglobin at physiological pH; (b) appropriate molecular geometry to fit the T-state binding pocket; and (c) recognition by the band 3 anion exchanger to permit transit across the erythrocyte membrane without cell lysis.

The solution was the installation of three cyclic pyrophosphate rings on the myo-inositol scaffold, creating a rigid, symmetric, polyanionic molecule with geometry complementary to the 2,3-DPG binding site and charge characteristics compatible with band 3 transport. The initial characterization was reported in a 2005 publication by Fylaktakidou, Lehn, Greferath, and Nicolau demonstrating that ITPP crossed the erythrocyte membrane, bound hemoglobin, and shifted the oxygen dissociation curve to the right in both purified hemoglobin solutions and whole blood [3].

3.2 Preclinical oncology development

The first major preclinical demonstration was the Kieda et al. (2006) report in Proceedings of the National Academy of Sciences showing that ITPP-treated erythrocytes suppressed HIF-1 α expression and angiogenesis in endothelial cells under hypoxic conditions in vitro, and that in vivo treatment suppressed tumor angiogenesis in a melanoma model [4]. This was followed by a series of publications from the Nicolau laboratory and collaborators demonstrating efficacy across multiple tumor models: hepatocellular carcinoma (eradication of early hepatoma tumors in rats with HIF-1 α suppression) [5]; pancreatic cancer (hypoxia reversion with

enhanced gemcitabine efficacy in rodent models) [6]; and a comprehensive vascular normalization study demonstrating PTEN activation, VEGF downregulation, and stable vessel normalization [7].

3.3 Cardiovascular and exercise physiology

The Duarte et al. (2010) ChemBioChem publication provided detailed characterization of the membrane permeation mechanism and the selectivity of band 3 transport [2]. In parallel, Biolo et al. (2009) demonstrated that ITPP treatment in a transgenic mouse model of severe heart failure (cardiac-specific overexpression of Gq-coupled receptor) produced a dose-dependent increase in maximal exercise capacity of up to 57 percent in normal mice and 63 percent in heart failure mice, published in Proceedings of the National Academy of Sciences [9]. Cardiovascular work expanded to include myocardial infarction models (protection from post-infarction heart failure and left ventricular remodeling) [10] and monocrotaline-induced pulmonary hypertension in rats (prevention of right ventricular failure and improved survival, published in the British Journal of Pharmacology in 2024) [11].

3.4 Clinical development

Normoxys, Inc., the company founded by Nicolau and Lehn to develop ITPP, advanced the compound to clinical trials under the designation OXY111A. A Phase Ib/IIa clinical trial protocol was published in BMC Cancer in 2016 [13]. The Phase Ib dose-escalation study (NCT02528526) was conducted at University Hospital Zurich between April 2015 and June 2018, with results published in Nature Communications in 2021 [12]. The trial established a maximum tolerated dose, demonstrated safety, and produced preliminary efficacy signals that the investigators recommended be followed by a powered Phase 2 trial comparing chemotherapy with and without preceding ITPP. As of the most recent available information, a Phase 2 trial has not been initiated, and the compound is not in active late-stage clinical development.

3.5 Anti-doping classification

The potential of ITPP to enhance oxygen delivery and exercise capacity led to its classification as a prohibited substance by the World Anti-Doping Agency (WADA) under the S2 category (peptide hormones, growth factors, related substances, and mimetics) and related prohibitions on substances that enhance oxygen transfer.

Detection methods using hydrophilic interaction liquid chromatography coupled with high-resolution mass spectrometry for human urine samples were developed and validated [14]. In parallel, detection methods for equine plasma were developed for horse racing anti-doping enforcement, reflecting concerns about potential performance enhancement in Thoroughbred racing [15, 16]. The compound has been detected in confiscated items in the racing context, though confirmed positive tests from competition samples remain rare, in part because the effective doses in horses (approximately 500 mg/kg, corresponding to approximately 250 grams per dose in a 500-kilogram horse) represent a logistical barrier to clandestine administration.

4. Mechanism of Action

ITPP exerts its biological effects through a single primary molecular mechanism: allosteric modulation of hemoglobin oxygen affinity. The downstream consequences of this mechanism, particularly in hypoxic tissues, produce a cascade of secondary molecular effects that constitute the pharmacological basis for the observed preclinical and clinical activity.

4.1 Hemoglobin allosteric modulation

Human adult hemoglobin (HbA) is an alpha-2 beta-2 tetramer that exists in dynamic equilibrium between two quaternary conformations: the high-affinity R-state (relaxed, oxygenated) and the low-affinity T-state (tense, deoxygenated). The equilibrium is regulated by allosteric effectors that bind the central cavity of the tetramer and stabilize the T-state, reducing oxygen affinity and promoting oxygen release. The principal endogenous allosteric effectors are protons (the Bohr effect), carbon dioxide (carbamino formation), chloride ions, and 2,3-diphosphoglycerate (2,3-DPG), which is present at near-equimolar concentration with hemoglobin within the erythrocyte [17].

ITPP binds the same central cavity site as 2,3-DPG, engaging the positively charged residues of the beta subunits (His-2, Lys-82, His-143) through electrostatic interactions with its six pyrophosphate-derived negative charges [2, 3]. The binding stabilizes the T-state conformation, reducing oxygen affinity and increasing the P50. In purified hemoglobin solutions, ITPP produces a concentration-dependent rightward shift of the oxygen dissociation curve. In whole blood, the compound enters erythrocytes via the band 3 anion exchange complex and produces a comparable shift, demonstrating functional membrane permeability [3].

The critical distinguishing property of ITPP relative to 2,3-DPG and to inositol hexakisphosphate (IP6, phytic acid) is membrane permeability. 2,3-DPG is synthesized within the erythrocyte by the Rapoport-Luebering pathway and cannot be administered exogenously to modulate hemoglobin in intact cells. IP6 binds hemoglobin with high affinity but cannot cross the erythrocyte membrane due to its six phosphomonoester groups and resulting high charge density. ITPP, with three

cyclic pyrophosphate rings instead of six discrete phosphate groups, presents a charge configuration compatible with band 3 anion transport, enabling exogenous administration and in situ allosteric modulation [2].

4.2 Downstream effects in hypoxic tumor tissue

The pharmacological consequence of enhanced oxygen delivery to hypoxic tumors produces a cascade of molecular events:

HIF-1alpha suppression. Tumor hypoxia stabilizes hypoxia-inducible factor 1-alpha (HIF-1alpha), a transcription factor that drives the expression of genes promoting angiogenesis (VEGF), metabolic reprogramming (glycolytic enzymes, glucose transporters), epithelial-mesenchymal transition, and immune evasion. ITPP-mediated reoxygenation restores normoxic degradation of HIF-1alpha via the prolyl hydroxylase-von Hippel-Lindau ubiquitin ligase pathway [4, 5].

VEGF downregulation and vascular normalization. Suppression of HIF-1alpha reduces VEGF expression, which, combined with ITPP-mediated activation of endothelial PTEN (phosphatase and tensin homolog), produces normalization of tumor vasculature [7]. Normalized vessels are more structurally organized, less permeable, and support improved perfusion, creating a therapeutic window during which subsequently administered chemotherapy or radiation therapy achieves greater tumor penetration and efficacy.

PTEN/AKT pathway activation. ITPP treatment activates endothelial PTEN, which antagonizes PI3K/AKT signaling, a pathway that drives pathological angiogenesis and endothelial cell survival in tumors. The PTEN activation reduces VEGF-induced vascular leakiness and promotes vessel maturation [7].

Radiation sensitization. Tumor hypoxia confers radioresistance because the cytotoxicity of ionizing radiation depends on the generation of reactive oxygen species from molecular oxygen (the oxygen fixation hypothesis). ITPP-mediated reoxygenation restores radiosensitivity by providing the molecular oxygen substrate for radiation-induced DNA damage [8, 18].

4.3 Downstream effects in cardiovascular hypoxia

In ischemic and failing myocardium, ITPP-mediated enhancement of oxygen delivery produces:

Improved myocardial pO₂. Direct measurement using fluorescent oxygen probes has demonstrated increased myocardial partial pressure of oxygen following ITPP treatment in models of post-infarction heart failure and pulmonary hypertension [10, 11].

Reduced expression of hypoxia-related proteins. Consistent with the tumor biology, cardiovascular tissue shows reduced HIF-1alpha, reduced VEGF, and reduced hypoxia-responsive gene expression following ITPP treatment [10].

Attenuation of pathological remodeling. The improved oxygen supply reduces ischemia-driven fibrosis, cardiomyocyte hypertrophy, and adverse ventricular geometry changes (dilation, wall thinning) that characterize heart failure progression [10, 11].

4.4 Anti-adiposity mechanism

Adipose tissue in obesity becomes hypoxic as tissue mass expands beyond the capacity of its vasculature. The resulting HIF-1alpha-driven inflammatory and fibrotic response contributes to insulin resistance and metabolic dysfunction. ITPP-mediated reversal of adipose hypoxia has been proposed and demonstrated in pre-clinical models to reduce adipose tissue accumulation and associated metabolic dysfunction in high-fat-diet-fed rodents [19].

5. Pharmacokinetics and Routes of Administration

5.1 Absorption and route of administration

ITPP is administered intravenously in both preclinical and clinical settings. The hexasodium salt is freely water-soluble and is formulated for intravenous infusion. Oral bioavailability has not been extensively characterized in published studies; the high polarity, multiple negative charges, and hydrophilicity of the compound predict poor oral absorption. The clinical formulation (OXY111A) is administered as an 8-hour intravenous infusion [12].

In preclinical rodent studies, ITPP has been administered both intravenously and intraperitoneally at doses ranging from 0.5 to 2 g/kg, with intraperitoneal administration producing measurable systemic exposure and pharmacological effect [9].

5.2 Distribution

The volume of distribution in the Phase Ib clinical study was 9.2 to 12.8 liters across dose cohorts, consistent with distribution primarily within the extracellular fluid compartment and intracellular erythrocyte compartment [12]. The compound distributes into erythrocytes via band 3 transport, which is the pharmacologically relevant compartment. Tissue distribution beyond the vascular and erythrocyte compartments has not been extensively characterized; the high polarity and charge of the compound predict limited penetration into lipophilic tissue compartments.

5.3 Metabolism and elimination

ITPP is not extensively metabolized. The compound is a fully oxidized inorganic pyrophosphate ester of myo-inositol, and no active or toxic metabolites have been identified. Elimination is primarily renal, with the intact compound excreted in urine. The terminal elimination half-life in the Phase Ib study ranged from 1.3 to 3.3 hours across dose cohorts [12]. Plasma clearance was 3.1 to 4.8 L/h, consistent across doses, indicating linear pharmacokinetics within the studied dose range. No

systemic accumulation was observed with repeated dosing; baseline plasma levels were undetectable before subsequent infusions on the every-other-day schedule [12].

5.4 Dose-exposure relationship

The Phase Ib study demonstrated dose-proportional pharmacokinetics. Peak plasma concentration (C_{max}) at 6 hours after infusion start increased dose-dependently from 47.2 mg/L at the lowest dose level (1,866 mg/m²) to 439.2 mg/L at the highest dose level (14,500 mg/m²). Area under the plasma concentration-time curve (AUC) increased proportionally from 350.7 h.mg/L to 2,864.1 h.mg/L across the dose range [12]. The dose-proportional pharmacokinetics and absence of accumulation simplify dose selection for future clinical studies.

5.5 Special populations

No formal studies of ITPP pharmacokinetics in renal impairment, hepatic impairment, pediatric, or geriatric populations have been published. Given the predominantly renal elimination, dose adjustment or enhanced monitoring may be appropriate in patients with significant renal impairment.

6. Preclinical Pharmacology

6.1 Oncology models

ITPP has been evaluated in at least seven preclinical tumor models:

Melanoma. The Kieda et al. (2006) PNAS study demonstrated that ITPP-treated erythrocytes suppressed hypoxia-induced HIF-1alpha and VEGF expression in endothelial cell co-cultures and inhibited tumor angiogenesis in a B16 melanoma model in vivo [4].

Hepatocellular carcinoma. Aprahamian et al. (2011) demonstrated that ITPP treatment led to HIF-1alpha suppression and eradication of early hepatoma tumors in rats [5].

Pancreatic cancer. Raykov et al. (2014) reported that ITPP-mediated hypoxia reversion controlled pancreatic cancer growth in rodents and enhanced gemcitabine efficacy, with synergistic life prolongation when combined with low doses of gemcitabine [6].

Vascular normalization model. Derbal-Wolfrom et al. (2013) published a comprehensive study in the Journal of Molecular Medicine demonstrating stable tumor vessel normalization with pO₂ increase and endothelial PTEN activation by ITPP, providing the mechanistic basis for the vascular normalization hypothesis [7].

Radiation sensitization studies. Tran et al. (2019) and Diepart et al. (2021) demonstrated that ITPP enhanced tumor oxygenation and radiation response in rodent tumor models, with increased initial and residual radiation-induced DNA damage as the primary mechanism for radiosensitization within previously hypoxic tumor regions [8, 18]. The administration of 2 g/kg ITPP once daily for 2 days led to tumor reoxygenation lasting at least 4 days. Both B16 melanoma and 4T1 breast tumors became more normoxic after ITPP treatment, with pO₂ levels elevated by 10 to 20 mmHg compared to control [18].

Glioblastoma. One study (Hartmann et al., 2017) failed to demonstrate enhancement of radiation therapy in a GL261 glioblastoma model, suggesting that the efficacy of ITPP-mediated radiosensitization may be tumor-type dependent and high-

lighting the importance of tumor-specific oxygenation dynamics [20].

Immune checkpoint potentiation. Recent work (2025) has demonstrated that ITPP-mediated reoxygenation can potentiate immune checkpoint blockade, as measured by photoacoustic imaging of tumor oxygen saturation, extending the therapeutic combination potential beyond chemotherapy and radiation [21].

6.2 Cardiovascular models

Heart failure and exercise capacity. The Biolo et al. (2009) PNAS study demonstrated that ITPP treatment in Gq-transgenic mice with severe heart failure produced a dose-dependent increase in maximal exercise capacity, with increases of up to 57 percent in normal mice and 63 percent in heart failure mice [9]. This landmark study established ITPP as a potential therapeutic for hypoxia-dependent cardiovascular disease.

Myocardial infarction. Okninska et al. (2020) in the Journal of Cellular and Molecular Medicine reported that ITPP treatment in a rat myocardial infarction model produced efficient protection from post-infarction heart failure and demonstrated recovery effects on left ventricular remodeling, with improved myocardial pO₂ and reduced expression of hypoxia-related proteins [10].

Pulmonary hypertension. Okninska et al. (2024) in the British Journal of Pharmacology demonstrated that ITPP prevented right ventricular failure and improved survival in monocrotaline-induced pulmonary hypertension in rats. Serial echocardiography documented attenuation of right ventricular dilation and dysfunction, and pressure-volume loop analysis confirmed preserved right ventricular contractile function with ITPP treatment [11].

6.3 Metabolic models

Nicolau and colleagues filed a patent (WO2014/143939) describing ITPP as an anti-obesity agent based on preclinical data demonstrating that ITPP treatment reduced the growth of white adipose tissue, visceral adipose tissue, and ectopic fat in high-fat-diet-fed rodent models through reversal of adipose tissue hypoxia [19]. Published peer-reviewed data on this application remain limited.

6.4 Safety pharmacology

Preclinical toxicology studies in rodents have not demonstrated significant organ toxicity at pharmacologically active doses. No mutagenicity, genotoxicity, or teratogenicity signals have been reported in published preclinical safety assessments. The compound is generally considered to have a favorable preclinical safety profile, consistent with its mechanism of action (modulation of an endogenous physiological parameter rather than direct receptor agonism or enzyme inhibition).

7. Clinical Evidence Base

7.1 Phase Ib dose-escalation study (NCT02528526)

The principal clinical evidence for ITPP comes from a Phase Ib dose-escalation study conducted at University Hospital Zurich, published in Nature Communications in 2021 [12].

Study design. Unrandomized, open-label, 3+3 dose-escalation design. Twenty-eight patients with advanced primary hepatopancreatobiliary malignancies (pancreatic ductal adenocarcinoma, n=10; cholangiocarcinoma, n=7; hepatocellular carcinoma, n=3) and colorectal cancer liver metastases (n=8) were enrolled between April 2015 and June 2018. Median age was 65 years. Twenty-five of 28 patients had received extensive prior therapy.

Dosing. ITPP (OXY111A) was administered as nine 8-hour intravenous infusions over three weeks (every other day, three infusions per week), across eight dose cohorts ranging from 1,866 to 14,500 mg/m² per dose.

Maximum tolerated dose. Two patients in the highest dose cohort (14,500 mg/m²) experienced dose-limiting toxicities (hypercalcemia grade II and grade IV), establishing the MTD at 12,390 mg/m² (the preceding dose level).

Efficacy under ITPP monotherapy. By RECIST 1.1 criteria, 52 percent (14/27 evaluable patients) achieved stable disease and 41 percent (11/27) had progressive disease during the ITPP monotherapy phase.

Metabolic response. By EORTC metabolic criteria, 41 percent had stable metabolic disease and 15 percent had partial metabolic response after ITPP treatment.

Response to subsequent chemotherapy. Following ITPP priming, patients received standard-of-care chemotherapy (median 3 cycles). By RECIST, 60 percent achieved stable disease and 10 percent achieved partial response. By EORTC metabolic criteria, 47 percent had stable metabolic disease and 27 percent had partial metabolic response.

Biomarker changes. Circulating angiogenic markers were reduced in a majority of patients after ITPP: VEGFA decreased in 44.4 percent, angiopoietin-1 in 51.9 percent, angiopoietin-2 in 59.3 percent, EGF in 85.2 percent, and PECAM1/CD31 in 66.7 percent. Patients with decreased angiogenic markers tended toward better radiological responses and survival after subsequent chemotherapy. VEGFA reduction was associated with extended median overall survival (398 versus 196 days, $p=0.053$); PECAM1 reduction correlated with improved survival (380 versus 171 days) [12].

Tissue correlate. Immunohistochemistry from one patient who provided tissue before and after ITPP demonstrated decreased CA9 (a hypoxia marker), decreased GLUT1 (glucose transporter), decreased vimentin (epithelial-mesenchymal transition marker), and increased ERG (a marker of vascular stability) [12].

Survival. Median progression-free survival was 48 days. Median overall survival was 206 days overall, with variation by tumor type: cholangiocarcinoma 302 days, colorectal liver metastases 340 days, hepatocellular carcinoma 684 days, and pancreatic ductal adenocarcinoma 165 days [12].

7.2 Phase 1a healthy volunteer study

A Phase 1a study in healthy volunteers was conducted prior to the Phase Ib oncology trial to establish initial safety and pharmacokinetics. Published details are limited; the study confirmed the absence of apparent toxicity and provided the pharmacokinetic foundation for dose selection in the oncology trial.

7.3 Current clinical development status

As of the most recent available information, a powered Phase 2 randomized trial comparing chemotherapy with and without preceding ITPP has been recommended by the Phase Ib investigators but has not been initiated. The compound is not in active late-stage clinical development for any indication. The cardiovascular and metabolic indications remain at the preclinical stage.

8. Sourcing and Quality Verification

ITPP hexasodium salt is available from multiple research chemical suppliers, including MedChemExpress (catalog number HY-100805), Cayman Chemical, Sigma-Aldrich/MilliporeSigma, Stanford Chemicals, SAM Materials, Invivochem, and SiChem GmbH. Reported purities are typically greater than or equal to 99 percent by HPLC. Research-grade material is supplied in quantities ranging from milligrams to grams; larger quantities for preclinical studies are available by custom synthesis from several suppliers.

The clinical-grade formulation (OXY111A) was manufactured under Good Manufacturing Practice conditions for the Phase Ib trial. Clinical-grade material is not commercially available; investigators requiring GMP-grade material would need to arrange custom manufacture.

Investigators should confirm compound identity and purity on every research-grade lot through:

- High-performance liquid chromatography (HPLC) purity assessment, with acceptance criterion of greater than or equal to 98 percent
- Mass spectrometry confirmation of molecular weight (electrospray ionization, negative mode; expected $[M-H]^-$ at m/z 604.97 for the free acid)
- Phosphorus-31 nuclear magnetic resonance spectroscopy to confirm the presence and symmetry of three cyclic pyrophosphate groups
- Karl Fischer titration or thermogravimetric analysis for residual water content (the compound is hygroscopic and water content affects accurate weighing)
- Endotoxin testing (Limulus amoebocyte lysate assay) for material intended for in vivo parenteral use
- Inductively coupled plasma mass spectrometry for heavy metal contamination if the synthesis employs metal catalysts

Third-party analytical laboratories can provide independent confirmation of vendor certificates of analysis. The ITPP research market is smaller than markets for more established research compounds; lot-to-lot variability should be anticipated and managed through on-receipt analytical verification.

9. Reconstitution and Handling

ITPP hexasodium salt is freely soluble in water and in aqueous buffers at neutral to alkaline pH. Reconstitution for research applications is straightforward:

Stock solution preparation. Dissolve the powder in sterile water for injection, phosphate-buffered saline, or normal saline. Concentrations of 50 to 200 mg/mL are readily achievable. The solution pH should be verified and adjusted to 7.0 to 7.5 with dilute hydrochloric acid or sodium hydroxide if necessary.

Clinical formulation. The OXY111A formulation was prepared as an intravenous infusion solution with calcium chloride added to the formulation to prevent chelation effects. This calcium chloride addition was the source of the asymptomatic hypercalcemia observed in the Phase Ib trial [12]. Investigators designing future clinical formulations should consider alternative approaches to calcium management.

Storage of solutions. Aqueous solutions should be stored at 2 to 8 degrees Celsius and used within 48 hours of preparation for non-preserved solutions, or within 14 days for solutions prepared in bacteriostatic water. The compound is stable in aqueous solution at neutral pH under refrigerated conditions for at least 7 days.

Storage of solid. The lyophilized or crystalline solid should be stored at 2 to 8 degrees Celsius under desiccation (the compound is hygroscopic). Under these conditions, stability is at least 24 months. Protect from moisture; brief exposure to ambient humidity during weighing is acceptable, but prolonged exposure will result in water uptake that affects gravimetric accuracy.

Sterilization. Solutions for in vivo use should be sterile-filtered through 0.22-micrometer polyethersulfone or polyvinylidene fluoride membranes. The compound is not compatible with autoclaving.

Infusion protocol (clinical). The Phase Ib protocol employed 8-hour intravenous infusions administered every other day, three times per week, for three consecutive weeks (nine infusions total) [12]. The prolonged infusion duration was selected to maintain sustained plasma levels during the infusion period and to manage tolerability at high dose levels. Preclinical protocols have employed shorter intravenous or intraperitoneal bolus administrations.

10. Stack Interactions and Combinations

The principal pharmacological interaction profile of ITPP derives from its mechanism of action (modulation of hemoglobin oxygen affinity) rather than from cytochrome P450 metabolism or receptor cross-reactivity. The compound is not metabolized by hepatic cytochrome P450 enzymes and is not expected to produce conventional drug-drug metabolic interactions.

Chemotherapy combinations. ITPP has been specifically studied in combination with gemcitabine in preclinical pancreatic cancer models, where the combination produced synergistic life prolongation relative to either agent alone [6]. The mechanism is improved drug delivery through vascular normalization and reversal of hypoxia-mediated chemoresistance. Similar potentiation is expected with other cytotoxic chemotherapy agents, and the Phase Ib investigators proposed that the angiogenic marker decreases observed after ITPP may identify patients most likely to benefit from subsequent chemotherapy [12].

Radiation therapy combinations. ITPP has been studied as a radiosensitizer in preclinical models, where tumor reoxygenation enhanced radiation-induced DNA damage and tumor response [8, 18]. The combination is mechanistically rational for any hypoxic tumor treated with external beam radiation.

Immune checkpoint inhibitors. Emerging preclinical data (2025) suggest that ITPP-mediated reoxygenation can potentiate immune checkpoint blockade [21]. Tumor hypoxia is a recognized driver of immunosuppressive microenvironment through HIF-mediated upregulation of PD-L1, accumulation of regulatory T cells, and exclusion of cytotoxic T lymphocytes. Reversal of hypoxia by ITPP may restore immune cell infiltration and function.

Other allosteric hemoglobin modulators. Concurrent use of ITPP with other hemoglobin allosteric effectors (efaproxiral, voxelotor) is pharmacologically redundant for right-shifting agents and contraindicated for left-shifting agents (voxelotor stabilizes the R-state, the opposite of ITPP). The combination has not been studied and is not recommended.

Erythropoiesis-stimulating agents. Concurrent use with erythropoietin or darbepoetin increases the total oxygen-carrying capacity (more hemoglobin) while ITPP increases the efficiency of oxygen unloading; the combination is mechanistically complementary and has been discussed in the cardiovascular literature [10].

Calcium-containing preparations. The OXY111A formulation contains calcium chloride; concurrent administration of additional calcium supplements or calcium-containing infusions may exacerbate the hypercalcemia observed in the Phase Ib trial [12].

Anticoagulants and antiplatelet agents. No specific interactions have been characterized. ITPP does not affect coagulation cascades or platelet function in published studies.

Chelating agents. The pyrophosphate groups of ITPP can chelate divalent cations. Concurrent administration with strong chelating agents (EDTA, deferoxamine) or with compounds that depend on divalent cation availability may produce interactions. This chelation potential is the reason calcium chloride was added to the clinical formulation.

11. Adverse Events and Safety

11.1 Clinical adverse events (Phase Ib)

The Phase Ib study recorded 56 adverse events total, of which 32 (57 percent) were assessed as treatment-related [12].

Hypercalcemia was the most common treatment-emergent toxicity, occurring in 67.9 percent (19/28) of patients. Grade I hypercalcemia was observed in 17 patients; grade II in 1 patient; grade IV (dose-limiting) in 1 patient. All patients with hypercalcemia remained asymptomatic. The hypercalcemia was attributed to the calcium chloride added to the OXY111A formulation to prevent chelation rather than to a direct pharmacological effect of ITPP. This finding suggests that reformulation without calcium chloride (or with reduced calcium content) could substantially reduce the incidence of this toxicity.

Electrolyte disturbances. Hypomagnesemia occurred in 17.9 percent of patients (grade I only). Hypophosphatemia occurred in 14.3 percent (grade I only). Hyperphosphatemia occurred in 3.6 percent (grade I, single patient). These disturbances are consistent with the polyphosphate chemistry of the compound and its potential for divalent cation chelation.

Hypertension occurred in 10.7 percent of patients (3 patients, grade I, transient). The mechanism is not fully characterized but may relate to acute changes in tissue oxygenation and compensatory vascular responses.

Dose-limiting toxicities. Two patients in the highest dose cohort (14,500 mg/m²) experienced dose-limiting toxicities consisting of hypercalcemia grade II and grade IV, establishing the MTD at 12,390 mg/m² [12].

Serious adverse events. Serious adverse events reported during the trial were assessed as unrelated to ITPP treatment.

11.2 Preclinical safety

Preclinical toxicology studies have demonstrated favorable safety at pharmacologically active doses. No organ toxicity, mutagenicity, genotoxicity, or teratogenicity has been reported. The compound does not interact with known off-target receptors or enzymes at concentrations relevant to the pharmacological effect.

11.3 Theoretical safety considerations

Polycythemia and hyperviscosity. Enhanced oxygen delivery efficiency could theoretically reduce erythropoietin-driven red cell production through feedback inhibition, but this has not been observed in preclinical or clinical studies at studied dose levels and durations.

Tissue hyperoxia. Excessive oxygen delivery to normoxic tissues could theoretically produce oxidative stress, but the allosteric mechanism is self-limiting: ITPP shifts the P50 but does not change the total oxygen-carrying capacity of hemoglobin, and the effect is most pronounced under conditions of low tissue pO₂ (where the steepest portion of the dissociation curve operates).

Chelation of essential divalent cations. The pyrophosphate moieties can chelate calcium, magnesium, and other divalent cations. This effect is managed in the clinical formulation by calcium chloride supplementation but should be monitored in investigational protocols, particularly with chronic dosing.

12. Comparative Assessment

This section presents a structured comparative assessment of five compounds that modulate oxygen delivery or hemoglobin function against ITPP, evaluated across five competency standards: novelty, effect size, promising potential, side-effect profile, and overall validation. The comparators were selected from the class of hemoglobin allosteric modulators and oxygen delivery agents that have produced material preclinical or clinical evidence.

12.1 Efaproxiral (RSR13)

Mechanism: Efaproxiral is a synthetic allosteric modifier of hemoglobin derived from the clofibrate class. It binds hemoglobin in the central cavity (similar to ITPP and 2,3-DPG) and shifts the oxygen dissociation curve to the right, enhancing oxygen release to tissues. Unlike ITPP, efaproxiral does not require membrane permeation; it binds hemoglobin in the plasma phase after binding to and dissociating from serum albumin [22].

Development trajectory: Allos Therapeutics developed efaproxiral through Phase 3 clinical trials as a radiation sensitizer for brain metastases from breast cancer. A Phase 3 trial (REACH study) in supplemental whole-brain radiation therapy for brain metastases was completed but did not meet its primary endpoint (overall survival in the intent-to-treat population), though a pre-specified subgroup analysis showed benefit in breast cancer patients. The compound received regulatory review but was not approved by the FDA. Development was discontinued following the negative Phase 3 readout.

Novelty: Low. The right-shift allosteric mechanism is shared with ITPP. The chemistry (small molecule, clofibrate-derived) is conventional. The compound was the first-in-class clinical candidate for hemoglobin allosteric right-shifting in oncology.

Effect size: Modest in the overall Phase 3 population; significant in the breast cancer brain metastases subgroup. Preclinical radiosensitization was robust.

Promising potential: Low. Development is terminated. The compound is not commercially available as a drug product.

Side-effect profile: The principal adverse events were hypoxemia (paradoxically, due to excessive right-shifting at high doses reducing arterial oxygen saturation), nausea, and fatigue. The hypoxemia signal is mechanistically informative for the ITPP class: excessive right-shifting of the dissociation curve can impair oxygen loading in the lungs. ITPP has not produced this signal, possibly because its allosteric effect is more moderate or because the self-limiting nature of band-3-mediated erythrocyte uptake constrains the degree of shift.

Overall validation: Moderate. The compound advanced through Phase 3 with a large clinical dataset. The radiation sensitization hypothesis was partially validated in subgroup analysis. The clinical program provides the most extensive human dataset for a right-shifting hemoglobin allosteric effector.

Comparison to ITPP: Both agents share the fundamental mechanism of hemoglobin allosteric right-shifting. ITPP has the advantage of membrane permeability (acting within the erythrocyte, the physiological compartment of hemoglobin), while efaproxiral acts in the extracellular phase. ITPP has the additional advantage of the vascular normalization and anti-angiogenic effects observed through the HIF/VEGF/PTEN cascade, effects not reported for efaproxiral. Efaproxiral has the advantage of a larger clinical dataset, including Phase 3 data, providing experience with human safety and dose-response at scale.

12.2 Voxelotor (GBT440, Oxbryta)

Mechanism: Voxelotor is a hemoglobin allosteric modifier that increases the oxygen affinity of hemoglobin (left-shift of the dissociation curve), stabilizing the R-state. It was developed and FDA-approved (2019) for the treatment of sickle cell disease, where the mechanism reduces hemoglobin S polymerization by maintaining hemoglobin in the oxygenated R-state conformation [23].

Development trajectory: Global Blood Therapeutics (now Pfizer, following acquisition) developed voxelotor through Phase 3 (HOPE study) and received FDA accelerated approval in November 2019 for sickle cell disease. In September 2024, Pfizer voluntarily withdrew voxelotor from the market after a post-approval confirmatory trial (HOPE-KIDS 2) did not demonstrate clinical benefit on vaso-occlusive crises despite hematological improvement (increased hemoglobin, reduced hemolysis markers).

Novelty: High for its specific indication (sickle cell disease). The left-shift mechanism is pharmacologically opposite to ITPP.

Effect size: Significant hematological effect (hemoglobin increase of approximately 1 g/dL). Clinical benefit on patient-relevant endpoints (vaso-occlusive crises) was not confirmed in the post-approval trial, leading to market withdrawal.

Promising potential: Low following market withdrawal. The compound is no longer commercially available.

Side-effect profile: Headache, diarrhea, abdominal pain, nausea, fatigue, and rash were the principal adverse events. Serious adverse events were infrequent.

Overall validation: Moderate. The compound achieved FDA approval (albeit accelerated) and generated a large clinical dataset, but the failure to confirm clinical benefit and subsequent market withdrawal substantially reduce validation.

Comparison to ITPP: Voxelotor operates in the opposite direction (left-shift versus right-shift) and targets a different disease state (sickle cell disease versus hypoxia-driven conditions). The comparison is instructive primarily as a demonstration that hemoglobin allosteric modulation is a clinically tractable pharmacological strategy, albeit one where hematological biomarker improvement does not guarantee clinical endpoint benefit. ITPP investigators should consider this cautionary precedent when designing clinical trials.

12.3 2,3-Diphosphoglycerate (2,3-DPG)

Mechanism: 2,3-DPG is the endogenous allosteric effector of hemoglobin produced by the Rapoport-Luebering pathway within erythrocytes. It binds the central cavity of deoxyhemoglobin and shifts the dissociation curve to the right. ITPP was explicitly designed to mimic 2,3-DPG function with the addition of membrane permeability [2].

Development trajectory: 2,3-DPG has not been developed as a therapeutic agent because it cannot be administered exogenously to modulate hemoglobin in intact erythrocytes. Strategies to increase endogenous 2,3-DPG (e.g., through pyruvate kinase modulation) are an active area of research for conditions with inappropriately low 2,3-DPG levels (e.g., stored blood transfusion).

Novelty: Not applicable (endogenous molecule, not a drug candidate).

Effect size: Physiological modulation of oxygen delivery is substantial; 2,3-DPG depletion in stored blood is a recognized contributor to transfusion-related oxygen delivery impairment.

Promising potential: Not applicable as a direct therapeutic agent. Indirect strategies (pyruvate kinase activators such as mitapivat) that modulate 2,3-DPG levels represent an alternative approach.

Side-effect profile: Not applicable.

Overall validation: The biology is thoroughly validated. The limitation is deliverability, which ITPP was designed to overcome.

Comparison to ITPP: 2,3-DPG is the biological template for ITPP. ITPP replicates the allosteric function with the critical addition of membrane permeability. The comparison validates the pharmacological rationale for ITPP.

12.4 Hemoglobin-based oxygen carriers (HBOCs)

Mechanism: HBOCs are cell-free hemoglobin preparations (cross-linked, polymerized, or PEGylated hemoglobin) designed to carry and deliver oxygen independently of erythrocytes. They increase oxygen-carrying capacity rather than modulating hemoglobin affinity [24].

Development trajectory: Multiple HBOCs have been developed and evaluated in clinical trials, including Hemopure (bovine polymerized hemoglobin, Biopure/HbO2 Therapeutics), PolyHeme (human polymerized hemoglobin, Northfield Laboratories), and Hemolink (human cross-linked hemoglobin, Hemosol). Clinical development has been marked by safety concerns, particularly hypertension (due to nitric oxide scavenging by cell-free hemoglobin) and increased mortality in meta-analyses. Hemopure is approved in South Africa for surgical anemia but is not approved in the United States or the European Union.

Novelty: Moderate. The concept is longstanding; specific formulations vary in chemistry and pharmacology.

Effect size: Oxygen delivery is measurably enhanced. Clinical outcomes have been compromised by safety signals.

Promising potential: Low to moderate. Active development continues for specific indications (trauma, surgical blood loss in settings where transfusion is unavailable), but the hypertension and mortality signals have substantially constrained the commercial trajectory.

Side-effect profile: Hypertension (nitric oxide scavenging), vasoconstriction, oxidative stress, renal toxicity, and increased mortality in pooled analyses are the principal concerns.

Overall validation: Low to moderate. Extensive clinical investigation has not produced broad regulatory approval. The safety profile is substantially less favorable than that of ITPP.

Comparison to ITPP: HBOCs and ITPP address the same fundamental problem (inadequate tissue oxygenation) through fundamentally different mechanisms. HBOCs increase the total oxygen-carrying capacity in the vascular space, while ITPP enhances the efficiency of oxygen unloading from existing hemoglobin within intact erythrocytes. ITPP has a substantially more favorable safety profile in clinical testing and does not produce the nitric oxide scavenging, vasoconstriction, and oxidative stress that have limited HBOC development. ITPP does not address conditions of absolute hemoglobin deficiency (acute hemorrhage) where HBOCs have their strongest rationale.

12.5 Mitapivat (AG-348, Pyrukynd)

Mechanism: Mitapivat is a first-in-class oral activator of pyruvate kinase-R (PKR), the erythrocyte-specific isoform of pyruvate kinase. By activating PKR, mitapivat increases glycolytic flux and ATP production in erythrocytes, which secondarily modulates 2,3-DPG levels and can affect hemoglobin oxygen affinity. FDA-approved (2022) for hemolytic anemia in pyruvate kinase deficiency [25].

Novelty: High. First-in-class mechanism. The approach of modulating endogenous 2,3-DPG through upstream metabolic activation is mechanistically distinct from direct allosteric hemoglobin modulation.

Effect size: Significant in pyruvate kinase deficiency (hemoglobin increases of 1 to 2 g/dL, reduced hemolysis). Investigated in thalassemia and sickle cell disease with mixed results.

Promising potential: Moderate to high. FDA-approved for pyruvate kinase deficiency. Under investigation in broader hemoglobinopathy and transfusion-dependent anemia indications.

Side-effect profile: Generally well tolerated. Insomnia, headache, and reduced estrogen levels (due to CYP enzyme induction) are the principal adverse events.

Overall validation: High for pyruvate kinase deficiency. Moderate for broader indications.

Comparison to ITPP: Mitapivat and ITPP both affect hemoglobin oxygen affinity, but through entirely different mechanisms: mitapivat modulates the endogenous 2,3-DPG pathway indirectly via glycolytic enzyme activation, while ITPP directly occupies the 2,3-DPG binding site. Mitapivat is orally bioavailable and FDA-approved; ITPP requires intravenous infusion and is investigational. The indications do not overlap substantially (mitapivat targets hereditary hemolytic anemias; ITPP targets acquired tissue hypoxia in cancer and cardiovascular disease).

12.6 Comparator summary

The five comparators span the pharmacological space of oxygen delivery modulation. **Efaproxiral** is the closest mechanistic comparator to ITPP (right-shift hemoglobin allosteric effector) but lacks membrane permeability and has been discontinued after Phase 3 failure. **Voxelotor** demonstrates that hemoglobin allosteric modulation can achieve regulatory approval but also that hematological biomarker improvement does not guarantee clinical benefit. **2,3-DPG** validates the biological rationale for ITPP as a deliverable analog of the endogenous effector. **HBOCs** address the same tissue oxygenation deficit through a different mechanism (increased carrying capacity rather than enhanced unloading) but carry a substantially worse safety profile. **Mitapivat** represents an alternative, oral, FDA-approved approach to modulating 2,3-DPG levels but targets different indications.

ITPP occupies a unique position in this comparator landscape as the only membrane-permeant allosteric effector of hemoglobin with demonstrated vascular normalization and anti-angiogenic downstream effects. Its preclinical profile is compelling across multiple therapeutic domains. The principal limitation relative to the comparators is the early stage of clinical development (Phase Ib completed, no Phase 2 or Phase 3 data) and the requirement for intravenous infusion. The favorable safety profile in the Phase Ib study, the dose-proportional pharmacokinetics,

and the preliminary signals of anti-angiogenic activity and chemotherapy potentiation support advancement to a powered Phase 2 trial. The voxelotor precedent (biomarker improvement without clinical benefit confirmation) is an important cautionary signal for the design of future ITPP trials, emphasizing the need for clinically meaningful primary endpoints rather than surrogate biomarker endpoints alone.

13. References

1. Shears SB. Diphosphoinositol polyphosphates: metabolic messengers? *Mol Pharmacol*. 2009;76(2):236-252.
2. Duarte CD, Greferath R, Nicolau C, Lehn JM. myo-Inositol trispyrophosphate: a novel allosteric effector of haemoglobin with high permeation selectivity across the red blood cell plasma membrane. *ChemBioChem*. 2010;11(17):2403-2410.
3. Fylaktakidou KC, Lehn JM, Greferath R, Nicolau C. Inositol tripyrophosphate: a new membrane permeant allosteric effector of haemoglobin. *Bioorg Med Chem Lett*. 2005;15(6):1605-1608.
4. Kieda C, El Hafny-Rahbi B, Collet G, et al. Suppression of hypoxia-induced HIF-1alpha and of angiogenesis in endothelial cells by myo-inositol trispyrophosphate-treated erythrocytes. *Proc Natl Acad Sci U S A*. 2006;103(42):15576-15581.
5. Aprahamian M, Bour G, Akladios CY, et al. Myo-InositolTrisPyroPhosphate treatment leads to HIF-1alpha suppression and eradication of early hepatoma tumors in rats. *ChemBioChem*. 2011;12(5):777-783.
6. Raykov Z, Grekova SP, Bour G, et al. Myo-inositol trispyrophosphate-mediated hypoxia reversion controls pancreatic cancer in rodents and enhances gemcitabine efficacy. *Int J Cancer*. 2014;134(11):2572-2582.
7. Derbal-Wolfrom L, Greco A, Diederich M, et al. Stable tumor vessel normalization with pO₂ increase and endothelial PTEN activation by inositol trispyrophosphate brings novel tumor treatment. *J Mol Med (Berl)*. 2013;91(4):457-464.
8. Tran LB, Bentley J, Bhogal N, et al. Impact of myo-inositol trispyrophosphate (ITPP) on tumour oxygenation and response to irradiation in rodent tumour models. *J Cell Mol Med*. 2019;23(3):1908-1916.
9. Biolo A, Greferath R, Sez DG, et al. Enhanced exercise capacity in mice with severe heart failure treated with an allosteric effector of hemoglobin, myo-inositol trispyrophosphate. *Proc Natl Acad Sci U S A*. 2009;106(6):1926-1929.

10. Okninska M, Paterek A, Zambrowska Z, et al. Treatment of hypoxia-dependent cardiovascular diseases by myo-inositol trispyrophosphate (ITPP): enhancement of oxygen delivery by red blood cells. *J Cell Mol Med*. 2020;24(3):2272-2283.
11. Okninska M, Paterek A, Kazimierczak W, et al. Myo-inositol trispyrophosphate prevents right ventricular failure and improves survival in monocrotaline-induced pulmonary hypertension in the rat. *Br J Pharmacol*. 2024;181(22):4550-4567.
12. Schulz GB, Greferath R, Goess C, et al. Phase Ib dose-escalation study of the hypoxia-modifier myo-inositol trispyrophosphate in patients with hepatopancreatobiliary tumors. *Nat Commun*. 2021;12(1):3807.
13. Limani P, Linecker M, Schneider MA, et al. Development of OXY111A, a novel hypoxia-modifier as a potential antitumor agent in patients with hepato-pancreato-biliary neoplasms: protocol of a first Ib/IIa clinical trial. *BMC Cancer*. 2016;16(1):812.
14. Gorgens C, Guddat S, Thomas A, et al. Screening and confirmation of myo-inositol trispyrophosphate (ITPP) in human urine by hydrophilic interaction liquid chromatography high resolution/high accuracy mass spectrometry for doping control purposes. *Drug Test Anal*. 2014;6(11-12):1102-1107.
15. Wong AS, Leung GN, Wan TS. Detection of myo-inositol trispyrophosphate (ITPP) in equine following an administration of ITPP. *Drug Test Anal*. 2013;5(8):560-566.
16. Wong JKY, Wan TS, Leung GNW. Doping control analysis of myo-inositol trispyrophosphate and 10 bisphosphonates in equine plasma by ion chromatography-mass spectrometry and its application to clodronic acid horse administration. *Drug Test Anal*. 2025;17(1):85-95.
17. Perutz MF. Stereochemistry of cooperative effects in haemoglobin. *Nature*. 1970;228(5273):726-739.
18. Diepart C, Karroum O, Tran LB, et al. Tumor oxygenation by myo-inositol trispyrophosphate enhances radiation response. *Int J Radiat Oncol Biol Phys*. 2021;110(4):1129-1139.

19. Nicolau C, Lehn JM, Greferath R. Myo-inositol trispyrophosphate as an anti-obesity agent. International Patent Application WO 2014/143939 A1. Filed March 14, 2014.
20. Hartmann KI, Bhargava HK, Gaines AS, et al. Failure of inositol trispyrophosphate to enhance highly effective radiotherapy of GL261 glioblastoma in mice. *Anticancer Res.* 2017;37(3):1121-1126.
21. Karroum O, Tran LB, et al. Potentiation of immune checkpoint blockade with an ITPP radiosensitizer studied with oxygen saturation measurements from photoacoustic imaging. *Sci Rep.* 2025;15:12483.
22. Suh JH, Stea B, Tankel K, et al. Results of the phase III trial of RSR13 (efaproxiral) and whole-brain radiation therapy for brain metastases. *Int J Radiat Oncol Biol Phys.* 2006;64(1):185-192.
23. Vichinsky E, Hoppe CC, Ataga KI, et al. A phase 3 randomized trial of voxelotor in sickle cell disease. *N Engl J Med.* 2019;381(6):509-519.
24. Natanson C, Kern SJ, Lurie P, Banks SM, Wolfe SM. Cell-free hemoglobin-based blood substitutes and risk of myocardial infarction and death: a meta-analysis. *JAMA.* 2008;299(19):2304-2312.
25. Grace RF, Rose C, Layton DM, et al. Safety and efficacy of mitapivat in pyruvate kinase deficiency. *N Engl J Med.* 2019;381(10):933-944.

This monograph is provided for research use only. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. ITPP (myo-inositol trispyrophosphate) is an investigational compound that has not been approved by the United States Food and Drug Administration or by the European Medicines Agency for any therapeutic indication. The compound is classified as a prohibited substance by the World Anti-Doping Agency. Investigators should consult their local regulatory authority and institutional review board before any human research application. Compound class generalizations are noted where compound-specific data are sparse; investigators should weight the evidence accordingly.